Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
145actual
Sites
139
Countries
Argentina, Austria, Brazil +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-26 | actual | When the study began enrolling |
| Primary completion | 2026-03-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-23 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chemotherapy-induced Thrombocytopenia
Interventions
- Drug: Romiplostim — also filed as Nplate
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of either a chemotherapy dose delay or reduction
measured 48 days
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed